期刊
IMMUNOTHERAPY
卷 11, 期 6, 页码 531-541出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2018-0131
关键词
adalimumab; biologic switch; brodalumab; etanercept; guselkumab; infliximab; ixekizumab; psoriasis; secukinumab; ustekinumab
类别
Aim: No guidelines exist for biologic switch in psoriasis after treatment failure. Although, switching between TNF-alpha antagonists has been reviewed, switching information about newer biologics is limited. Materials & methods: We did a thorough systematic review from 'PubMed' and 'Embase', which includes new biologics such as IL-12/IL-23 antagonists, IL-17A antagonists and IL-23 antagonists. Results & conclusion: New biologics such as IL-17 antagonist or IL-23 antagonist show greater responses in bio-experienced patients and could even be used for patients in whom previous treatments failed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据